REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
05/04/2026
Back to search
Official data from USPTO
OMBLASTYS (OMBURTAMAB)
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
05/05/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
04/24/2020
Registration date
05/04/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/04/2021
Last transaction
05/05/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
03
Owner location
New York, NY, US
Examiner
FRENCH, CURTIS W
Law office
O30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized, capitalized, purple word "OMBLASTYS" with three stacked V-shapes emanating from the top of the letter "Y", with the first in purple, the second in light green, and the third in teal. Centered beneath the word "OMBLASTYS", in all lower-case letters, in a different font, and in parentheses, is the word "OMBURTAMAB" in gray.
Holders and representatives
Holders
Y-mAbs Therapeutics, Inc
Representatives
Andrew N. Spivak MOSAIC LEGAL GROUP, PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer
Class 42
Research and development services in the field of antibodies; research and development services in the field of antibody technology; laboratory research and analysis services relating to the production of antibodies; scientific and technological servicesscientific researchanalysistesting in the field of antibodiesresearch and design relating thereto; industrial analysis and research services in the field of antibodies
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/04/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/16/2021
PUBO
PUBLISHED FOR OPPOSITION
02/16/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/27/2021
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
08/27/2020
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
08/21/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/20/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/20/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/20/2020
ALIE
ASSIGNED TO LIE
08/17/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
07/29/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
07/24/2020
GNSL
LETTER OF SUSPENSION E-MAILED
07/24/2020
CNSL
SUSPENSION LETTER WRITTEN
07/24/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
07/20/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/20/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
07/20/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/20/2020
DOCK
ASSIGNED TO EXAMINER
07/17/2020
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
05/07/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/06/2020
NWAP
NEW APPLICATION ENTERED
04/28/2020
Continuous trademark protection
Get notified about every new filing that threatens OMBLASTYS (OMBURTAMAB) or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.